Dr. Margolis is the second fellow named to the Lankenau-Israel Strategic Alliance (LISA) program, which was launched in 2017.The program’s mission is to develop collaborations between physicians and scientists at Lankenau Medical Center and medical centers in Israel. Under the umbrella of the Israel Heart Society, the program fosters mutually beneficial cardiology research.
Dr. Margolis was awarded a medical degree from Tel Aviv University and trained in internal medicine at Tel Aviv Medical Center where he was board-certified in 2015. He completed his clinical fellowship in cardiology and then was appointed senior clinical consultant in cardiology at Tel Aviv Medical Center. He was selected to participate in the LISA program by the Israel Heart Society via a nationwide competition.
“We are honored to welcome Dr. Margolis to LIMR and look forward to working with him to help advance both his cardiology training and our own research initiatives,” said Charles Antzelevitch, PhD, executive director of cardiovascular research at LIMR and director of research, Lankenau Heart Institute, who helped to initiate the LISA program.
Dr. Margolis will spend the first year of his LISA fellowship in a basic science training program, working with Dr. Antzelevitch and his research team at LIMR. Some of the research in which he will participate will include studies to determine:
Why patients with cancer are prone to developing atrial fibrillation and how best to treat them
Mechanisms leading to inherited J wave syndromes and therapies to prevent sudden cardiac death in these patients.
“Lankenau is known for being a leader in cardiac care delivery and research, so I am thrilled to help advance the work being done here,” said Dr. Margolis. “I look forward to collaborating with Main Line Health researchers and clinicians in their important work of diagnosing and treating cardiovascular disease.”
In addition to Drs. Antzelevitch and Kowey, the LISA initiative was developed by Mark Cohen, a member of Lankenau’s President’s Advisory Council, and Dr.Michael Glikson, past president of the Israel Heart Society. The program is being funded by Mr. Cohen and other local donors, along with Lankenau Medical Center and the Israel Heart Society.
About Main Line Health
Founded in 1985,Main Line Health is a not-for-profit health system serving portions of Philadelphia and its western suburbs. Main Line Health’s commitment—to deliver advanced medicine to treat and cure disease while also playing an important role in prevention and disease management as well as training physicians and other health care providers—reflects our intent to keep our community and ourselves well ahead. A team of more than 10,000 employees and 2,000 physicians care for patients throughout the Main Line Health system.
At Main Line Health’s core are four of the region’s most respected acute care hospitals—Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital—as well as one of the nation’s recognized facilities for rehabilitative medicine, Bryn Mawr Rehabilitation Hospital.
Main Line Health also includes Mirmont Treatment Center for drug and alcohol recovery; Main Line Health HomeCare & Hospice, which includes skilled home health care, hospice and home infusion services; Main Line Health Centers, primary and specialty care, lab and radiology, and other outpatient services located in Broomall, Collegeville, Concordville, Exton, King of Prussia and Newtown Square; Lankenau Institute for Medical Research, a biomedical research organization; and Main Line HealthCare,one of the region’s largest multispecialty physician networks.
Main Line Health is the recipient of numerous awards for quality care and service, including System Magnet® designation, the nation’s highest distinction for nursing excellence and the Mid-Atlantic Alliance for Performance Excellence (MAAPE) Excellence Award. Main Line Health is committed to creating an environment of diversity, respect and inclusion and has proudly embraced the American Hospital Association’s #123forEquity Pledge to Act to eliminate disparities in care. We are dedicated to advancing patient-centered care, education and research to help our community stay healthy.
About Lankenau Institute for Medical Research
Lankenau Institute for Medical Research (LIMR) is a nonprofit biomedical research institute located on the campus of Lankenau Medical Center and is part of Main Line Health. Founded in 1927, LIMR’s mission is to improve human health and well-being. Faculty and staff are devoted to advancing innovative new approaches to formidable medical challenges, including cancer, cardiovascular disease, gastrointestinal disorders and autoimmune diseases, such as diabetes and arthritis. LIMR’s principal investigators conduct basic, preclinical and translational research, using their findings to explore ways to improve disease detection, diagnosis, treatment and prevention. They are committed to extending the boundaries of human health through technology transfer and training of the next generation of scientists and physicians.